Abstract 199P
Background
Neutrophils, the most efficient defenders against pathogens, are essential for tumor microenvironment balance and homeostasis. However, given their plasticity and short half-life which made them too fragile to be profiled, it poses complex challenges regarding how neutrophils are imprinted and adapt specific fates across cancers.
Methods
Here we designed a one-two-punch sorting strategy, generated the neutrophil atlas from 225 samples of 144 patients from 17 cancer types, and further developed a computational pipeline to recover both shared and specific transcriptional programs.
Results
Unexpectedly, neutrophils harbored extraordinary complexity composed of 10 cell states and showed sharp tissue or phenotypic specialty. We observed and verified that cancer neutrophils are dramatically arranged along tumor-specific terminal differentiation paths such as inflammation, angiogenesis and antigen-presenting. In particular, the antigen-presenting program was associated with better patient outcomes in the majority of cancers. Such a program can be evoked by leucine metabolism and is dependent on mitochondrial remodeling, acetyl-CoA generation, and preferable epigenetic histone H3K27ac modification. Functionally, antigen-presenting neutrophils invoked expanded T cell response and neoantigen-specific reactiveness. We finally designed the antigen-presenting neutrophil immunotherapy (adoptive transferring and leucine diet) which fine-tunes the microenvironment balance and fuels anti-PD-1 immunotherapy.
Conclusions
In summary, these data not only lay the groundwork for future neutrophil research, and open the black box of neutrophil state divergence across cancers, but also unravel minimally invasive therapeutic opportunities including adoptive transferring antigen-presenting neutrophils.
Legal entity responsible for the study
The author.
Funding
NSFC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract